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Commentary
Commentaries on ‘Antibiotics for prolonged moist cough
in children’ with a response from the review authors
These are commentaries on a Cochrane review, published in the issue of EBCH, first published as: Marchant
JM, Morris PS, Gaffney J, Chang AB. Antibiotics for prolonged moist cough in children. Cochrane Database
of Systematic Reviews 2005, Issue 4. Art. No.: CD004822. DOI: 10.1002/14651858.CD004822.pub2.
Further information for this Cochrane review is available in this issue of EBCH in the accompanying Summary
article.
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Commentary by Bruce K. Rubin
Acute cough in children is most commonly due to a
viral respiratory infection such as the common cold.
There is clearly no benefit to using antibiotics to treat
acute viral respiratory infections, and antibiotics do
not decrease the severity or frequency of coughing.
On the other hand, there is evidence supporting the
use of antibiotic therapy in some young children with
cough lasting for more than 3 weeks as it is postu-
lated that many of these children will have bacteria
and neutrophils in their airway signifying protracted
bacterial bronchitis (1); protracted bacterial bronchitis
is considered a form of ‘nonspecific’ cough; or cough
that cannot be attributed to common conditions like
postnasal drip, asthma, gastroesophageal reflux and
bronchiectasis including cystic fibrosis. Nonetheless,
the existence of protracted bacterial bronchitis as a
clinical diagnosis remains controversial.
This review examines the results of two studies
evaluating the use of antibiotics compared with either
placebo or no therapy in children younger than 7 years
who have prolonged moist cough of duration more
than 10 days. This is distinct from both acute cough
and chronic dry cough. The evidence suggests that
administration of antibiotics will decrease the severity
and duration of coughing in some of these children.
However, the studies used for this analysis contain
heterogeneous populations and methodological flaws,
which make these recommendations less than robust.
Furthermore, almost all children with prolonged moist
cough eventually have spontaneous resolution of their
symptoms and there is no clear evidence that with-
holding antibiotics from children with prolonged moist
cough will lead to long-term adverse outcomes.
Critically, these recommendations are limited to
children younger than 7 years who also have a ‘moist
cough’ and have had this cough for at least 10 days.
These limited data cannot be extrapolated to other
patient groups. While there is no value in using
antibiotics to treat an acute respiratory tract infection
or a common cold, there is a risk that these data
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may be misinterpreted to imply that moist cough in
children should be treated using an antibiotic before
an acute viral infection has been given the opportunity
to spontaneously resolve.
The potential for overuse of antibiotics is a major
problem and has led to the widespread develop-
ment of bacterial resistance to commonly used antibi-
otics. Antimicrobial stewardship has been an important
focus of evidence-based therapy over the past decade.
Thus, it is extremely important that antibiotics not be
overused to treat a symptom that can be self-limiting.
It is also important to balance the risk of antibiotic use
which may be understated in this review. Allergy to
penicillin is not uncommon in children and can be seri-
ous. Less common, but life threatening, is the risk of
severe unanticipated adverse effects such as Stevens-
Johnson syndrome.
Our understanding of the role of bacteria and
airway inflammation in producing chronic cough in
children is evolving, and should lead to more rational
selection of patient populations who would benefit
from appropriate intervention with antibiotic therapy.
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Response by author
We thank Professor Rubin for his interest in the
subject and his commentary. We however, respectfully
disagree with many of his points. Firstly, protracted
bacterial bronchitis (PBB) is not considered a form
of ‘nonspecific’ cough (1). Nonspecific cough, as
described about 13 years ago refers to ‘dry cough in
the absence of identifiable respiratory illness’ (2).
Secondly, although we were the first group to label
PBB as a clinical entity (so as to improve recognition
and thus appropriate treatment) (3), the concept of
cough resulting from endobronchial infection and
inflammation in the airways is far from new, as
outlined by Everard (4). Indeed, this association has
also been described in adults (5), and in papers
from previous decades. Pathobiological studies (6–8)
and clinical observations suggest many patients with
chronic, wet cough have bronchitis initially that,
if persistent and left untreated, may evolve into
bronchiectasis (9,10). Animal studies have shown that
infection is a necessary condition for the development
of bronchiectasis, as experimentally imposed bronchial
stenosis in the absence of infection does not lead to
bronchiectasis distal to the obstruction (11).
Thirdly, in our current era, PBB is internationally
accepted (12,13), increasingly recognized (14,15) and
has been incorporated into paediatric guidelines in
many countries (16–19). Increasingly, pathobiological
studies relating to PBB and wet cough in general are
published (20–22).
Fourthly, the statement that ‘almost all children
with prolonged moist cough eventually have sponta-
neous resolution of their symptoms’ is not referenced.
Clearly, resolution with placebo treatment does occur
(substantial improvement at follow up was seen in
36% and 21% in the two trials included in our review).
However, this is much more likely in children who
receive antibiotics as reflected in the number needed
to treat for benefit of 3 (95%CI = 4–5) (23). InAQ3
support of this, the progression of illness, as defined
by requirement for further antibiotics in both papers
(24,25), was significantly lower in the treatment group
(pooled OR = 0.10; 95%CI = 0.03–0.34). The num-
ber needed to treat to avoid progression of disease was
4 (95%CI= 3–5) (23). Before antibiotics were discov-
ered and widely available, not every exposed individ-
ual succumbed to infection and the clinical symptoms
of the same type of infection varied among patients.
Clearly, host response factors play a key role in deter-
mining clinical presentation and subsequent course of
infection.
We do agree that the studies in the Cochrane
review contain methodological flaws (as stated in our
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Cochrane review) (23). The two randomized controlled
trials (24,25) in the Cochrane review were studies
published in the early 1990s and the methodology
issues must be interpreted in the context of that era.
The post-CONSORT era started in 1998. However,
there are very few randomized controlled trials on pro-
longed cough in children; the authors (24,25) of these
randomized controlled trials are commended on their
foresight. The conclusions of our Cochrane review
(and earlier studies) are now further strengthened by
recent studies. Our recent multi-centre national study
involving 346 children (26), as well as a double-blind
placebo-controlled randomized controlled trial (sup-
ported by bronchoalveolar data) (27) lend further sub-
stantial support: for the clinical entity of PBB; that
use of appropriate antibiotics is efficacious and; that
treatment significantly improves cough and parental-
proxy cough-specific (PC-QOL) and generic (PedsQL)
quality of life. We agree with Professor Rubin that
antibiotics are not without side effects. Parents should
be informed of both the likely benefits and harms when
considering this treatment option. Finally, it is impor-
tant that clinicians are cognizant that although most
chronic wet cough in the absence of other symptoms
and signs is PBB, not all wet cough is PBB (28), and
that the management of acute cough differs from that
for chronic cough.
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